Clinical Trial Update: TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update for TBio-4101 with pembrolizumab, with or without chemotherapy, in recurrent or metastatic head and neck squamous cell carcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• TBio-4101

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING